ISRCTN74851494 https://doi.org/10.1186/ISRCTN74851494

A study to assess the period effect (and the effect of food) on processing by the body of RO7268489 following single oral-dose administration in healthy participants

Submission date 06/07/2023	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 10/07/2023	**Overall study status** Completed	
Last Edited 03/10/2024	**Condition category** Other	

Plain English summary of protocol

Background and study aims
RO7268489 (study drug) is an experimental drug, which means that Health Authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved RO7268489 for the treatment of any disease yet. The purpose of this study is to investigate how quickly and to what extent RO7268489 is taken up, modified, distributed, and removed from the body (this is called pharmacokinetics or PK). The study will also assess if PK is different if RO7268489 is given a second time and test if there is a difference in PK when RO7268489 is given under fasted or fed conditions (i.e., after fasting or after a meal). This study also aims to find out whether RO7268489 at a dose of 1 mg has any effects (good or bad) on healthy participants.

Who can participate?
Healthy males and females of 18 to 54 years of age

What does the study involve?
Participants will have to be a part of this study for approximately 92 days. This study will be conducted in two parts, Part 1 and Part 2. Based on when the participants enrol in the study, they may be placed in any one part of the study. Both parts of the study will have the following periods:
1. Screening Period: Participants will have to undergo some tests and/or procedures before the study starts to make sure that they are eligible for taking part in the study. It may take up to 8 weeks to complete the screening procedures. The participants may have to visit the clinic more than once during this period.
2. In-Clinic Period: Parts 1 and 2 of the study are further divided into two periods, Period 1, and Period 2. In both study parts (1 and 2) participants will be admitted to the study centre twice, once during Period 1 and once during Period 2. During both periods, participants will be admitted two days before the study drug is administered (i.e., Day -2) and will stay in the clinical unit for 4 nights (5 days). They will be allowed to go back home 48 hours after study drug

administration (i.e., Day 3) and after completing all the study tests.
a. Part 1 [“Period Effect” (PE)]: Participants will receive a single dose of RO7268489 by mouth on Day 1 of Period 1 and Period 2 after an overnight fast of at least 10 hours. Between the two periods, participants will have 1 to 3 weeks’ time during which they will not receive the study medication, this is called the wash-out period.
Part 2 [“Food effect” (FE)]: RO7268489 will be administered to the participants 2 times: once under fasted conditions (overnight fasting) and once under fed conditions (after breakfast), with a washout period in between. Participants will be assigned by chance to receive the study drug first under fasted or fed conditions.
3. Ambulatory Visits: In both Parts 1 and 2, participants will have to report to the clinic on prespecified days for check-ups.
4. Follow-up Visit: The participant will have to come back for the final safety follow-up visit on Day 92 after the second study drug administration. This is to check on the participants' health after treatment is completed.

What are the possible benefits and risks of participating?
RO7268489 is an experimental drug and is being given purely for research purposes, it is not intended that participants will receive any benefit from this study. But the information learned from this study may be useful to treat future patients.
The participants may have side effects from the study drug or procedures used in this study. Side effects can vary from mild to very serious and may be different from person to person.
RO7268489 has had limited testing in humans, there may potentially also be side effects that are not known at this time. The known side effects of this drug, as well as potential side effects, are listed below.
1. Allergic reactions on treatment with RO7268489, which can be in the form of itching, difficulty breathing, a rash, and/or a drop in blood pressure.

There may be a risk in exposing an unborn child to study the drug, and all risks are not known at this time. Women who are pregnant, become pregnant, or who are currently breastfeeding, cannot participate in this study.

Where is the study run from?
F. Hoffmann-La Roche Ltd (USA)

When is the study starting and how long is it expected to run for?
February 2023 to March 2024

Who is funding the study?
F. Hoffmann-La Roche Ltd (USA)

Who is the main contact?
global.trial_information@roche.com

Contact information

Type(s)
Public

Contact name
Dr Clinical Trials

Contact details
Building 1, Grenzacherstrasse 124
Basel
Switzerland
CH-4070
+41 616878333
global.trial_information@roche.com

Additional identifiers

Clinical Trials Information System (CTIS)
2023-503528-25-00

Protocol serial number
BP44618

Study information

Scientific Title
A single-center, open-label, adaptive, two-period, single oral dose, phase I study to assess the period effect (and the effect of food) on the pharmacokinetics of RO7268489 in healthy participants

Study objectives
The purpose of this study is to assess the period effect on the pharmacokinetics (PK) of a single oral dose of RO7268489 in healthy participants. In addition, the study will also assess the effect of food on the PK of single oral doses of RO7268489 in healthy participants.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 01/06/2023, BEBO Foundation for the Assessment of Ethics of Biomedical Research (Doctor Nassaulaan 10, Assen, 9401 HK, Netherlands; +31 (0) 592 405 871; info@stbebo.nl), ref: Not available

Primary study design
Interventional

Study design
Phase I open-label adaptive two period single-center study
Part 1: non-randomized two-period design
Part 2: randomized two-period cross-over design

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Healthy participants

Interventions
Part 1: Participants will receive a single oral dose of RO7268489, 1 milligram (mg), on Day 1 of Period 1 after an overnight fast of at least 10 hours. Following a washout period of 1-3 weeks participants will then receive another single oral dose of RO7268489, 1 mg, on Day 1 of Period 2 under fasted condition.

Part 2: Fasted/Fed Sequence: Participants will receive a single oral dose of RO7268489, 1 mg, on Day 1 of Period 1 after an overnight fast of at least 10 hours. Following a washout period of 1-3 weeks participants will then receive a second oral dose of RO7268489, 1 mg, on Day 1 of Period 2 under fed condition i.e., after having breakfast.

Part 2: Fed/Fasted Sequence: Participants will receive a single oral dose of RO7268489, 1 mg, on Day 1 of Period 1 under fed condition i.e., after having breakfast. Following a washout period of 1-3 weeks participants will then receive a second oral dose of RO7268489, 1 mg, on Day 1 of Period 2 after an overnight fast of at least 10 hours.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
RO7268489

Primary outcome(s)
1. Part 1: Area under the plasma concentration time curve (AUC) of RO7268489 (and its metabolite[s] as appropriate) calculated using standard non-compartmental methods from samples collected at pre-dose and multiple time-points post-dose from Day 1 up to follow-up visit on Day 92
2. Part 1: Maximum observed plasma concentration (Cmax) of RO7268489 (and its metabolite[s] as appropriate) calculated using standard non-compartmental methods from samples collected at pre-dose and multiple time-points post-dose from Day 1 up to follow-up Visit on Day 92
3. Part 2: AUC of RO7268489 (and its metabolite[s] as appropriate) under fasted and fed conditions calculated using standard non-compartmental methods from samples collected at pre-dose and multiple time-points post-dose from Day 1 up to follow-up visit on Day 92
4. Part 2: Cmax of RO7268489 (and its metabolite[s] as appropriate) under fasted and fed conditions calculated using standard non-compartmental methods from samples collected at pre-dose and multiple time-points post-dose from Day 1 up to follow-up visit on Day 92

Key secondary outcome(s)
1. Parts 1 and 2: Number of participants with adverse events (AEs) and severity of AEs graded as mild, moderate and severe from screening up to follow-up visit on Day 92
2. Parts 1 and 2: Concentration of RO7268489 calculated using standard non-compartmental methods from samples collected at pre-dose and multiple timepoints post-dose up to Day 15
3. Parts 1 and 2: RO7268489-related change on pharmacodynamics (PD) biomarker measured using validated liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) method from samples collected at pre-dose and multiple timepoints post-dose up to Day 22
4. Parts 1 and 2: RO7268489-related change on PD biomarker in serum measured using validated LC-MS/MS method from samples collected at pre-dose and multiple time-points post-dose up to Day 22

Completion date
20/02/2024

Eligibility

Key inclusion criteria
1. Male or female participants who are overtly healthy (defined by absence of evidence of any active or chronic disease)
2. Body mass index (BMI) within the range of 18 to 32 kilograms per square meter (kg/m2) (inclusive)

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Upper age limit
54 Years

Sex
All

Total final enrolment
24

Key exclusion criteria
1. History of malignancy in the past 5 years
2. History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs.
3. Vaccination within 6 weeks prior to Day 1 including influenza and/or SARS-CoV-2/ COVID-19 vaccination.

Date of first enrolment
18/07/2023

Date of final enrolment
11/10/2023

Locations

Countries of recruitment
Netherlands

Study participating centre
ICON
Netherlands
9728

Sponsor information

Organisation
F. Hoffmann-La Roche

Funder(s)

Funder type
Industry

Funder Name
F. Hoffmann-La Roche

Alternative Name(s)
Hoffman-La Roche, F. Hoffmann-La Roche Ltd.

Funding Body Type
Private sector organisation

Funding Body Subtype
For-profit companies (industry)

Location
Switzerland

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are not expected to be made available due to participant-level data not being a regulatory requirement.

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes